■这项研究调查了莫努比拉韦治疗患有精神疾病的非住院COVID-19患者的临床疗效。
这项回顾性队列研究使用TriNetX研究网络来确定在2022年1月1日至2023年5月1日期间经历非住院COVID-19的精神疾病患者。使用倾向评分匹配(PSM)方法将接受莫那普拉韦(治疗组)的患者与未接受莫那普拉韦(未治疗组)的患者进行匹配。结果包括短期结果-30天内全因住院或死亡的综合结果,以及COVID-19诊断后一年内发生COVID-19后疾病的风险。
■两组9421例患者,每个都具有平衡的基线特征,使用PSM方法鉴定。在30天的随访中,与未治疗组相比,治疗组住院或死亡风险降低(HR,0.760;95%CI,0.665-0.869)。与未治疗组相比,治疗组也表现出经历COVID-19后病症的风险降低,包括胸部/喉咙疼痛(HR,0.615;95%CI,0.543-0.696),异常呼吸(HR,0.761;95%CI,0.687-0.884),腹部症状(HR,0.748;95%CI,0.674-0.831),疲劳(HR,0.718;95%CI,0.638-0.808),头痛(HR,0.753;95%CI,0.665-0.852),认知症状(HR,0.769;95%CI,0.630-0.940),肌痛(HR,0.647;95%CI,0.530-0.789),咳嗽(HR,0.867;95%CI,0.770-0.978),和心悸(HR,0.641;95%CI,0.534-0.770),随访1年。
■Molnupiravir可能与较低的全因住院率或死亡率有关,并且在患有精神疾病的非住院COVID-19患者中,也降低了COVID-19后疾病的风险。
UNASSIGNED: This study investigated the clinical effectiveness of
molnupiravir for treating non-hospitalized COVID-19 patients with pre-existing psychiatric disorder.
UNASSIGNED: This retrospective cohort study used the TriNetX research network to identify patients with psychiatric disorder who experienced non-hospitalized COVID-19 between 1 January 2022, and 1 May 2023. The propensity score matching (PSM) method was used to match patients receiving
molnupiravir (treated group) with those who did not (untreated group). The outcome included short-term outcomes - the composite of all-cause hospitalization or death within 30 days and the risk of post-COVID-19 conditions up to a year after COVID-19 diagnosis.
UNASSIGNED: Two groups of 9,421 patients, each with balanced baseline characteristics, were identified using the PSM method. During the 30-day follow-up, treated group was associated with a reduced risk of hospitalization or mortality compared to untreated group (HR, 0.760; 95% CI, 0.665-0.869). Compared to untreated group, treated group also exhibited a decreased risk of experiencing post-COVID-19 conditions, including chest/throat pain (HR, 0.615; 95% CI, 0.543-0.696), abnormal breathing (HR, 0.761; 95% CI, 0.687-0.884), abdominal symptoms (HR, 0.748; 95% CI, 0.674-0.831), fatigue (HR, 0.718; 95% CI, 0.638-0.808), headache (HR, 0.753; 95% CI, 0.665-0.852), cognitive symptoms (HR, 0.769; 95% CI, 0.630-0.940), myalgia (HR, 0.647; 95% CI, 0.530-0.789), cough (HR, 0.867; 95% CI, 0.770-0.978), and palpitation (HR, 0.641; 95% CI, 0.534-0.770) during the 1-year follow-up.
UNASSIGNED: Molnupiravir could be associated with lower rates of all-cause hospitalization or death and also lower risk of post-COVID-19 condition among non-hospitalized COVID-19 patients with pre-existing psychiatric disorder.